WEREWOLF THERAPEUTICS INC. - COMMON STOCK

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

08 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

22 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

14 Nov 2023 16:25:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

03 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

31 Oct 2023 09:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

27 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

11 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

05 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

10 Aug 2023 07:10:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

01 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

11 May 2023 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in May Investor Conferences

01 May 2023 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

19 Apr 2023 10:00:15 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

23 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023

16 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023

15 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330

24 Feb 2023 07:30:03 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference

07 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting

10 Nov 2022 09:00:02 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

10 Nov 2022 07:00:01 By Nasdaq GlobeNewswire